Celldex clears Phase 3 CSU trials, but efficacy details remain undisclosed

Celldex is a clinical-stage biotech whose central business bet is barzolvolimab, with the company previously expecting its pivotal CSU readout in September/October 2026 and planning a BLA submission in 2027. The pivotal efficacy hurdle was cleared in both studies. EMBARQ-CSU1 and EMBARQ-CSU2 each met the primary endpoint and all key secondary endpoints, with treatment continuing through 52 weeks. 〔0〕 That is better than merely reproducing the encouraging Phase 2 profile: it validates the mechanism in two large registration studies totaling 1,939 patients. 〔1〕 The result materially advances Celldex toward commercialization. The company now has the core clinical result needed to support its stated 2027 BLA plan, and the release says efficacy was sustained or deepened through Week 24 with a safety profile consistent with prior Phase 2 experience. 〔2〕 〔3〕 The headline is stronger than the disclosure detail. Celldex provides no numerical UAS7 changes, response rates, placebo-adjusted effect sizes, subgroup results, or detailed adverse-event tables, saying the data will be presented at an upcoming medical meeting. That leaves the size of the benefit, the claimed differentiation in omalizumab-refractory patients, and the commercial positioning still to be verified. Bottom line: This is a genuine pivotal-trial win that moves barzolvolimab from a promising Phase 2 program toward a regulatory filing. It clears the main clinical bar, but the investment-relevant magnitude and differentiation remain undisclosed until the full dataset is presented.